Skip to Main Content

A Randomized Phase II Study to Evaluate Efficacy of T-DM1 With or Without Palbociclib in the Treatment of Patients With Metastatic HER2 Positive Breast Cancer

Conditions

Breast - Female | Breast

Phase II

What is the purpose of this trial?

This is a randomized phase II study to evaluate if the combination of T-DM1 with palbociclib improves progression-free survival compared to single agent T-DM1in patients with metastatic HER2 positive breast cancer

  • Trial with
    University of Arizona Cancer Center
  • Start Date
    01/21/2019
  • End Date
    08/20/2021

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    04/15/2021
  • Study HIC
    #2000023405